Shell Asset Management Co. Has $1.41 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Shell Asset Management Co. reduced its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.3% in the 4th quarter, HoldingsChannel reports. The firm owned 5,992 shares of the biopharmaceutical company’s stock after selling 205 shares during the quarter. Shell Asset Management Co.’s holdings in Alnylam Pharmaceuticals were worth $1,410,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ALNY. Larson Financial Group LLC increased its holdings in Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares in the last quarter. R Squared Ltd purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $33,000. OFI Invest Asset Management bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $35,000. Colonial Trust Co SC bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $35,000. Finally, IFP Advisors Inc lifted its position in shares of Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 47 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Up 0.7%

ALNY stock opened at $285.31 on Friday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $146.79 and a 1-year high of $304.39. The business has a fifty day moving average price of $253.73 and a 200-day moving average price of $253.58. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a market capitalization of $37.20 billion, a P/E ratio of -131.48 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same period in the previous year, the business posted ($0.16) EPS. The business’s revenue was up 20.2% compared to the same quarter last year. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Citigroup raised their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a research report on Friday, March 21st. Scotiabank boosted their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a “sector outperform” rating in a report on Monday, March 31st. UBS Group increased their target price on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a “buy” rating in a report on Friday, May 2nd. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $280.00 to $328.00 in a research report on Monday, March 24th. Finally, StockNews.com upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $319.17.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares of the company’s stock, valued at $3,240,344.36. This represents a 10.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Pushkal Garg sold 1,548 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,017,271.63. The trade was a 11.44% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.